NCT00790387View on ClinicalTrials.gov

Tirofiban and Enoxaparin in High Risk Coronary Intervention

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2006

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Enoxaparin

Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg

DRUG

Tirofiban

DRUG

unfractionated heparin

Trial Locations (1)

4032

The Prince Charles Hospital, Brisbane

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Prince Charles Hospital

OTHER_GOV